NDA 022512 · Boehringer Ingelheim
Pradaxa
Dabigatran Etexilate Mesylate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Oct 19, 2010
Approved uses
4
Original approval plus efficacy supplements
Registered trials
250
45 Phase 3, 26 recruiting
FAERS reports
73,751
56,526 serious, 10,958 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning (A) PREMATURE DISCONTINUATION OF PRADAXA INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including PRADAXA, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if PRADAXA is discontinued for a reason other than pathological bleeding or completion of a course of therapy ( 2.6 , 2.7 , 2.8 , 5.1 ). (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with PRADAXA who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may...
What it is approved for
From the label in effect Jun 25, 2025.
PRADAXA Capsules is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 ) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients PRADAXA Capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. 1.2 Treatment of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5-10 days. 1.3 Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients PRADAXA Capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. 1.4 Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery PRADAXA Capsules is...
Mechanism: Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors. Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus. Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 21, 2021 Supplement 41 · Efficacy · priority review LabelLetterPatient Package Insert
- Nov 20, 2015 Supplement 28 · Efficacy LetterLabel
- Apr 4, 2014 Supplement 18 · Efficacy LabelLetter
- Oct 19, 2010 Original approval · Type 1 - New Molecular Entity · priority review NovelOther Important Information from FDALabelReview
3 products under this application
- PRADAXA · DABIGATRAN ETEXILATE MESYLATE EQ 110MG BASE · CAPSULE, ORAL · Prescription · TE AB
- PRADAXA · DABIGATRAN ETEXILATE MESYLATE EQ 75MG BASE · CAPSULE, ORAL · Prescription · TE AB
- PRADAXA · DABIGATRAN ETEXILATE MESYLATE EQ 150MG BASE · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dabigatran Etexilate" as an intervention, any sponsor and status, largest first.
- Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran EtexilatePivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00262600 · 18,113 participants · Start Dec 2005 · Primary completion Apr 2009
Drug: warfarin; Dabigatran dose 1 and 1 more · For: Atrial Fibrillation; Stroke
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 984 sites in all
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationPivotal-lookingActive, not recruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT03129490 · 11,000 participants (planned) · Start Apr 1, 2023 · Primary completion Oct 30, 2027
Drug: Dabigatran Etexilate Oral Capsule; Rivaroxaban Oral Tablet and 2 more · For: Atrial Fibrillation; Atrial Flutter
Sites: Aalborg, Denmark; Aarhus, Denmark; Ballerup Municipality, Denmark · 38 sites in all
- RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY TrialPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00808067 · 5,897 participants · Start Nov 2008 · Primary completion Dec 2012
Drug: dabigatran dose 1; dabigatran dose 2 · For: Atrial Fibrillation
Sites: Birmingham, Alabama; Mobile, Alabama; Lake Havasu City, Arizona · 567 sites in all
- Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02239120 · 5,390 participants · Start Nov 27, 2014 · Primary completion Aug 14, 2018
Drug: optional ASA as comedication; placebo to ASA and 4 more · For: Stroke; Secondary Prevention
Sites: Phoenix, Arizona; Beverly Hills, California; El Cajon, California · 569 sites in all
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)Pivotal-lookingActive, not recruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT03129555 · 5,000 participants (planned) · Start Apr 1, 2023 · Primary completion Mar 31, 2027
Drug: Dabigatran Etexilate Oral Capsule; Rivaroxaban Oral Tablet and 2 more · For: Deep Vein Thrombosis; Pulmonary Embolism
Sites: Aarhus, Denmark; Copenhagen, Denmark; Copenhagen NV, Denmark · 26 sites in all
- Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)Pivotal-lookingStatus unknown
The First Affiliated Hospital with Nanjing Medical UniversityAcademic, hospital or other
NCT03234114 · 3,746 participants (planned) · Start Feb 3, 2018 · Primary completion Dec 31, 2024
Drug: Triple antithrombotic therapy; Dual antithrombotc therapy-1 and 1 more · For: Acute Coronary Syndrome (ACS); Non-valvular Atrial Fibrillation (NVAF)
Sites: Nanjing, China
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial FibrillationPivotal-lookingStatus unknown
National Cheng-Kung University HospitalAcademic, hospital or other
NCT02666157 · 3,672 participants (planned) · Start Jan 2016 · Primary completion Dec 2018
Drug: Dabigatran etexilate; Rivaroxaban and 1 more · For: Atrial Fibrillation
Sites: Tainan, Taiwan; Dou-Liou City, Taiwan; Kaohsiung City, Taiwan · 5 sites in all
- OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled TrialPivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT03759938 · 3,648 participants · Start Jun 18, 2019 · Primary completion May 30, 2024
Drug: Direct oral anticoagulant (DOAC) · For: Stroke, Acute; Atrial Fibrillation
Sites: Aberystwyth, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 44 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- gastrointestinal haemorrhage7,976
- cerebrovascular accident3,968
- fall3,079
- haemorrhage3,048
- anaemia2,661
- ischaemic stroke2,199
- death2,144
- dyspnoea2,084
- rectal haemorrhage2,010
- dizziness1,985
- atrial fibrillation1,801
- diarrhoea1,704
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 5 |
| 2008 | 3 |
| 2009 | 4 |
| 2010 | 410 |
| 2011 | 11,548 |
| 2012 | 9,133 |
| 2013 | 7,940 |
| 2014 | 7,200 |
| 2015 | 4,610 |
| 2016 | 5,590 |
| 2017 | 6,566 |
| 2018 | 5,564 |
| 2019 | 3,960 |
| 2020 | 2,994 |
| 2021 | 2,513 |
| 2022 | 2,217 |
| 2023 | 1,166 |
| 2024 | 976 |
| 2025 | 832 |
| 2026 | 520 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Pradaxa (Dabigatran Etexilate Mesylate)
2024 spending
$123M
Beneficiaries
139,514
481,836 claims
Per beneficiary
$883
$1.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $599,577,175 |
| 2021 | $571,018,502 |
| 2022 | $469,904,882 |
| 2023 | $176,220,137 |
| 2024 | $123,182,256 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review and meta-analysis of dabigatran peak and trough concentration in adults.
Ng JW, Mohd Tahir NA, Chin PKL, et al. · Br J Clin Pharmacol 2022 · Meta-Analysis, Systematic Review
- Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C, Koskinen M, Fricke R, et al. · Eur J Drug Metab Pharmacokinet 2019 · Clinical Trial, Phase I
- Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.
Ferro JM, Coutinho JM, Dentali F, et al. · JAMA Neurol 2019 · Comparative Study, Multicenter Study
- Human Variability in Carboxylesterases and carboxylesterase-related Uncertainty Factors for Chemical Risk Assessment.
Di Consiglio E, Darney K, Buratti FM, et al. · Toxicol Lett 2021 · Comparative Study, Meta-Analysis
- The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
Abatzis-Papadopoulos M, Tigkiropoulos K, Nikas S, et al. · Orthop Traumatol Surg Res 2023 · Meta-Analysis, Systematic Review
- Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
Kansal AR, Zheng Y, Pokora T, et al. · Best Pract Res Clin Haematol 2013 · Systematic Review
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.